{"schema_version":"secwatch.filing_event.v1","accession":"0001549084-22-000069","form_type":"8-K","ticker":"CHRN","cik":"0001549084","company_name":"EKSO BIONICS HOLDINGS, INC.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.103672+00:00","generated_at":"2026-06-22T08:58:25.031238+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ekso Bionics Q3 revenue up 9.2% to $3.3M; net loss widens to $4.3M; record 33 EksoNR bookings","bullets":["Revenue $3.3M (+9.2% YoY); nine-month revenue $9.4M (+30.6% YoY).","Record bookings of 33 EksoNR units in Q3; driven by increase in international orders.","Gross margin fell to 51% in Q3 from 59% a year ago due to higher service and supply chain costs.","Net loss applicable to common stockholders $4.3M ($0.33 per share) vs $2.0M ($0.15) in Q3 2021.","Cash position $29.2M at Sept 30, 2022, down from $40.4M at Dec 31, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001549084-22-000069","json":"https://secwatch.observer/filing/0001549084-22-000069.json","markdown":"https://secwatch.observer/filing/0001549084-22-000069.md","text":"https://secwatch.observer/filing/0001549084-22-000069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549084/000154908422000069/0001549084-22-000069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549084/000154908422000069/ekso-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:58:25.031238+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2f63f7211df74ae6be21d27dad4a95b7e1e37658","claim":"EKSO BIONICS HOLDINGS, INC. reported third quarter ended September 30, 2022 results: revenue $3.3 million, net income $4.3 million, EPS $0.33 per basic and diluted share.","evidence_excerpt":"results for the three months ended September 30, 2022. Recent Highlights and Accomplishments • Record of 33 EksoNR bookings in the third quarter of 2022 • Reported revenue of $3.3 million in the third quarter of 2022, an increase of 9.2% year-over-year • Reported revenue of $9.4 million in the first nine months of 2022, an increase of 30.6% year-over-year • Strong","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549084/000154908422000069/0001549084-22-000069-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$3.3 million"},{"label":"Net income","value":"$4.3 million"},{"label":"EPS","value":"$0.33 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"4d8ce202cb9991ede44f44d74fd48fd0912ab738","claim":"EKSO BIONICS HOLDINGS, INC. reported nine months ended September 30, 2022 results: revenue $9.4 million, net income $11.9 million, EPS $0.92 per basic and diluted share.","evidence_excerpt":"of 33 EksoNR bookings in the third quarter of 2022 • Reported revenue of $3.3 million in the third quarter of 2022, an increase of 9.2% year-over-year • Reported revenue of $9.4 million in the first nine months of 2022, an increase of 30.6% year-over-year • Strong cash position of $29.2 million as of September 30, 2022 “Our third quarter results reflected","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549084/000154908422000069/0001549084-22-000069-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"nine months ended September 30, 2022"},{"label":"Revenue","value":"$9.4 million"},{"label":"Net income","value":"$11.9 million"},{"label":"EPS","value":"$0.92 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}